Hemab Therapeutics (COAG) stake rises as RA Capital buys 67,669 shares
Rhea-AI Filing Summary
Hemab Therapeutics Holdings, Inc. reported that investment entities affiliated with RA Capital Management, a ten percent owner, made open-market purchases of Common Stock. On June 16, 2026, an affiliated fund bought 61,523 shares at a weighted average price of $24.98 per share, with trades ranging from $24.55 to $25.00. On June 15, 2026, another affiliated fund bought 6,146 shares at a weighted average price of $24.89 per share, within a $24.65 to $25.00 range. Following these transactions, one indirect position reported 6,444,637 shares, while related fund holdings were reported at 354,938 and 1,009,052 shares, all held indirectly and subject to pecuniary-interest-only ownership disclaimers.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 67,669 shares
Net Buy
4 txns
Insider
RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M.
Role
10% Owner | 10% Owner | 10% Owner | 10% Owner
Bought
67,669 shs ($1.69M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 61,523 | $24.98 | $1.54M |
| Purchase | Common Stock | 6,146 | $24.89 | $153K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 7,808,627 shares (Indirect, See footnotes)
Footnotes (1)
- The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.55 to $25.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus II Fund, L.P. (the "Nexus Fund II") and RA Capital Nexus IV Fund, L.P. (the "Nexus Fund IV"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. Held directly by the Fund. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.65 to $25.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Held directly by Nexus Fund II. Held directly by Nexus Fund IV.
Key Figures
Open-market purchase 1: 61,523 shares at $24.98
Open-market purchase 2: 6,146 shares at $24.89
Total net shares bought: 67,669 shares
+5 more
8 metrics
Open-market purchase 1
61,523 shares at $24.98
Common Stock bought on June 16, 2026; weighted average price
Open-market purchase 2
6,146 shares at $24.89
Common Stock bought on June 15, 2026; weighted average price
Total net shares bought
67,669 shares
Net buy shares across reported purchase transactions
Indirect position after June 16
6,444,637 shares
Total shares following June 16, 2026 purchase entry
Fund holding 1
354,938 shares
Indirect Common Stock holding as of June 15, 2026
Fund holding 2
1,009,052 shares
Indirect Common Stock holding as of June 15, 2026
Price range trade 1
$24.55–$25.00
Range for June 16, 2026 weighted average price calculation
Price range trade 2
$24.65–$25.00
Range for June 15, 2026 weighted average price calculation
Key Terms
open-market purchase, weighted average price, ten percent owner, indirect ownership, +1 more
5 terms
open-market purchase financial
"transaction_action is described as an open-market purchase of Common Stock"
An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
ten percent owner financial
"RA Capital entities are marked as a ten percent owner of the issuer."
indirect ownership financial
"total_shares_following_transaction is reported with ownership type indirect."
pecuniary interest financial
"The Adviser and related parties disclaim beneficial ownership except for pecuniary interest."
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider activity did RA Capital report for Hemab Therapeutics (COAG)?
Entities affiliated with RA Capital reported open-market purchases of Hemab Therapeutics Common Stock. Two affiliated funds bought a combined 67,669 shares, and the reporting group remains a ten percent owner with several large indirect shareholdings disclosed.
What are RA Capital’s indirect Hemab Therapeutics (COAG) holdings after these transactions?
After the reported purchases, one indirect position shows 6,444,637 shares. Separate entries list fund holdings of 354,938 shares and 1,009,052 shares. All positions are reported as indirect ownership through investment funds managed by RA Capital affiliates.
What do the weighted average prices in the Hemab Therapeutics (COAG) Form 4 mean?
The reported prices are weighted averages across multiple trades. For example, the $24.98 figure reflects purchases between $24.55 and $25.00. RA Capital undertakes to provide detailed trade-by-trade pricing information to the issuer, security holders, or SEC staff upon request.